Oncolix Inc. (fka ONCX)

[reaper247]

LOL namtae,

Oncolix about to go sub penny? Shareholders recognizing the fleecing the company is giving them with massive dilution bringing fully diluted outstanding shares close to or over 1,000,000,000

LOL, “fully diluted....”

Preferred shares and warrants do not count toward the O/S or float until they are actually converted.

Not here, not on any OTC and not on any NASDAQ or NYSE company.

Does an AAPL or GOOG include their warrants, notes, options issued, vested and/or unvested into the current O/S and apply that to their market caps?

OF course not. Why do some people insist that the term “fully diluted” applies only to ONCX?

The actual ONCX O/S has remained relatively unchanged.

ONCX currently has a market cap of just $1,155,000 based on the actual O/S and PPS.

Also, the filings show that note holders agreed to renegotiate the terms of the notes that seem to be favorable to current ONCX shareholders.

"...The convertible notes bear interest at a rate of 10% per annum, with accrued interest payable commencing April 1, 2019, then on the first day of each calendar month thereafter until maturity..."

If note holders are electing to not convert preferred shares and warrants into common shares as of yet, while also agreeing to accrued interest payable commencing April 1, 2019, what real risk of dilution are ONCX shareholders really facing short/medium term?

But thats nothing. The next funding coming soon will raise that number into the multibillions

LOL, lets not forget Sherry Grisewoods who was recently added to the ONCX BOD.

Didn’t the previous public company that she was BOD member, recently secure roughly $20,000,000 in grants and non-dilutive financing that launched the PPS of that company?

Oh yes here it is. This is from the other company that she served as a BOD member.

…We expect our expenses to continue at a similar pace through 2018 primarily to continue funding our in-process Phase II clinical trials. Two of our clinical studies are expected to be funded by a total of $17.1 million of grants made by the DOD to the Mayo Clinic. Our collaborators at Mayo Clinic announced a $3.8 million grant which we expect would fully fund a Phase II clinical trial in DCIS that we had planned for our HER2/neu+ vaccine…

ONCX is near/at an all time PPS low with very little downside remaining at this point, while looking at potential gains of anywhere to 1000%-5000+%.

Remember that GHS/ONCX has a history of securing non-dilutive funding in the form of grants from the Susan G. Komen Foundation and the US government.

ONCX is looking good based on currently available public information.

IMO and FWIW.